Merck Immunotherapy Drug Shines In Lung Cancer Study – WPSU
WPSU |
Merck Immunotherapy Drug Shines In Lung Cancer Study
WPSU There’s encouraging news for cancer treatments that stimulate the immune system to attack cancer cells. A widely used immunotherapy drug appears to be useful in a greater number of patients with lung cancer. The drug called Keytruda, or pembrolizumab … Merck Immunotherapy Drug Shines In Lung Cancer Study | WFAEWFAE |
NBCNews.com |
Merck Immunotherapy Drug Shines In Lung Cancer Study
NPR There’s encouraging news for cancer treatments that stimulate the immune system to attack cancer cells. A widely used immunotherapy drug appears to be useful in a greater number of patients with lung cancer. The drug called Keytruda, or pembrolizumab … Immunotherapy transforms lung cancer, the biggest cancer killerNBCNews.com Immunotherapy scores big win against lung cancer in studyCBS News Treatment combo nearly doubles survival time in lung cancer patients, study findsCNN Washington Post all 43 news articles » |
Daily Monitor (press release) (blog) |
New stem cell therapy improves vision after blindness
WNDU-TV Alison Milianta lost her vision due to a brain tumor a few years ago. “You panic,” she said, “It’s almost like you’re in an earthquake. It’s like everything is closing in on you.” Then, she found retinal specialist Dr. Jeffrey Weiss. “I will not accept … Stem cell therapy giving hope to autistic childrenDaily Monitor (press release) (blog) Clay specks turn stem cells into bone and cartilageFuturity: Research News Basel Researchers Succeed in Cultivating Cartilage from Stem CellsR & D Magazine Stuff.co.nz –BSI bureau (press release) all 31 news articles » |
|
Preclinical data show potential effectiveness of CRISPR Therapeutics’ off-the-shelf CAR–T cells; shares up 2% after …
Seeking Alpha Gene editor CRISPR Therapeutics (NASDAQ:CRSP) is up 2% after hours on modest volume on the heels of its announcement of encouraging preclinical data supporting the potential efficacy of its off-the-shelf CAR-T candidates. The results were presented at … |
|
Preclinical data show potential effectiveness of CRISPR Therapeutics’ off-the-shelf CAR–T cells; shares up 2% after …
Seeking Alpha Gene editor CRISPR Therapeutics (NASDAQ:CRSP) is up 2% after hours on modest volume on the heels of its announcement of encouraging preclinical data supporting the potential efficacy of its off-the-shelf CAR-T candidates. The results were presented at … |